Literature DB >> 25735852

Unfavorable neurological outcome in diabetic patients with acute ischemic stroke is associated with incomplete recanalization after intravenous thrombolysis.

Huan Tang1, Sheng Zhang1, Shenqiang Yan1, David S Liebeskind2, Jianzhong Sun3, Xinfa Ding3, Minming Zhang3, Min Lou1.   

Abstract

OBJECTIVE: To assess the impact of diabetes on neurological outcome and recanalization in acute ischemic stroke (AIS) after intravenous thrombolysis (IVT).
METHODS: Clinical data of 419 consecutive patients with AIS who received IVT between June 2009 and April 2014. Based on the medical history and new diagnosis, the patients were divided into groups with and without diabetes. Neurological outcomes at 24 h, 7 days and 3 months after IVT were evaluated. Favorable outcome was defined as National Institutes of Health Stroke Scale (NIHSS) score decrease ≥4 points from baseline or 0 at 24 h, NIHSS decrease ≥8 points or 0 at day 7, or modified Rankin scale ≤1 at 3 months after IVT. Recanalization on non-invasive imaging was evaluated in patients with large vessel occlusion (LVO) according to thrombolysis in myocardial infarction grades.
RESULTS: Among 419 patients, 98 (23.4%) had diabetes. Multivariable analyses showed that comorbidity of diabetes was an independent predictor of unfavorable outcome at 24 h (OR=0.534, 95% CI 0.316 to 0.903, p=0.019), at day 7 (OR=0.382, 95% CI 0.220 to 0.665, p=0.001), and at 3 months (OR=0.464, 95% CI 0.266 to 0.808, p=0.007). In patients with LVO, diabetes was an independent predictor of incomplete recanalization 24 h after IVT (OR=0.268, 95% CI 0.075 to 0.955, p=0.042).
CONCLUSIONS: Diabetic patients with AIS had unfavorable neurological outcome, potentially linked to incomplete recanalization after IVT. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  Stroke; Thrombolysis

Mesh:

Year:  2015        PMID: 25735852     DOI: 10.1136/neurintsurg-2014-011643

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  10 in total

1.  The Impact of Diabetes Mellitus and Admission Hyperglycemia on Clinical Outcomes after Recanalization Therapies for Acute Ischemic Stroke: STAY ALIVE National Prospective Registry.

Authors:  Peter Janos Kalmar; Gabor Tarkanyi; Zsofia Nozomi Karadi; Laszlo Szapary; Edit Bosnyak
Journal:  Life (Basel)       Date:  2022-04-25

Review 2.  Clinical Variables and Genetic Risk Factors Associated with the Acute Outcome of Ischemic Stroke: A Systematic Review.

Authors:  Nuria P Torres-Aguila; Caty Carrera; Elena Muiño; Natalia Cullell; Jara Cárcel-Márquez; Cristina Gallego-Fabrega; Jonathan González-Sánchez; Alejandro Bustamante; Pilar Delgado; Laura Ibañez; Laura Heitsch; Jerzy Krupinski; Joan Montaner; Joan Martí-Fàbregas; Carlos Cruchaga; Jin-Moo Lee; Israel Fernandez-Cadenas
Journal:  J Stroke       Date:  2019-09-30       Impact factor: 6.967

3.  Association between CHADS2, CHA2DS2-VASc, ATRIA, and Essen Stroke Risk Scores and Unsuccessful Recanalization after Endovascular Thrombectomy in Acute Ischemic Stroke Patients.

Authors:  Hyung Jun Kim; Moo-Seok Park; Joonsang Yoo; Young Dae Kim; Hyungjong Park; Byung Moon Kim; Oh Young Bang; Hyeon Chang Kim; Euna Han; Dong Joon Kim; JoonNyung Heo; Jin Kyo Choi; Kyung-Yul Lee; Hye Sun Lee; Dong Hoon Shin; Hye-Yeon Choi; Sung-Il Sohn; Jeong-Ho Hong; Jong Yun Lee; Jang-Hyun Baek; Gyu Sik Kim; Woo-Keun Seo; Jong-Won Chung; Seo Hyun Kim; Sang Won Han; Joong Hyun Park; Jinkwon Kim; Yo Han Jung; Han-Jin Cho; Seong Hwan Ahn; Sung Ik Lee; Kwon-Duk Seo; Yoonkyung Chang; Tae-Jin Song; Hyo Suk Nam
Journal:  J Clin Med       Date:  2022-01-05       Impact factor: 4.241

4.  Effect of Diabetes on Post-stroke Recovery: A Systematic Narrative Review.

Authors:  Seoyon Yang; Mathieu Boudier-Revéret; SuYeon Kwon; Min Yong Lee; Min Cheol Chang
Journal:  Front Neurol       Date:  2021-12-14       Impact factor: 4.003

5.  Factors Associated with Unfavorable Functional Outcomes After Intravenous Thrombolysis in Patients with Acute Ischemic Stroke.

Authors:  Nat Satumanatpan; Warinyupa Tonpho; Nutchanon Thiraratananukulchai; Pheerawat Chaichanamongkol; Pittawat Lekcharoen; Kitti Thiankhaw
Journal:  Int J Gen Med       Date:  2022-03-25

Review 6.  Diabetes Mellitus/Poststroke Hyperglycemia: a Detrimental Factor for tPA Thrombolytic Stroke Therapy.

Authors:  Yinghua Jiang; Ning Liu; Jinrui Han; Yadan Li; Pierce Spencer; Samuel J Vodovoz; Ming-Ming Ning; Gregory Bix; Prasad V G Katakam; Aaron S Dumont; Xiaoying Wang
Journal:  Transl Stroke Res       Date:  2020-11-02       Impact factor: 6.829

7.  The prognostic significance of large vessel occlusion in stroke patients treated by intravenous thrombolysis.

Authors:  Justyna M Derbisz; Marcin Wnuk; Tadeusz Popiela; Jeremiasz Jagiełła; Roman Pułyk; Joanna Słowik; Tomasz Dziedzic; Wojciech Turaj; Agnieszka Słowik
Journal:  Pol J Radiol       Date:  2021-06-11

Review 8.  Prevalence of diabetes and its effects on stroke outcomes: A meta-analysis and literature review.

Authors:  Lik-Hui Lau; Jeremy Lew; Karen Borschmann; Vincent Thijs; Elif I Ekinci
Journal:  J Diabetes Investig       Date:  2018-10-13       Impact factor: 4.232

9.  Risk Factors Associated with Outcomes of Recombinant Tissue Plasminogen Activator Therapy in Patients with Acute Ischemic Stroke.

Authors:  Yi-Ju Tseng; Ru-Fang Hu; Shin-Tyng Lee; Yu-Li Lin; Chien-Lung Hsu; Shih-Wei Lin; Chia-Wei Liou; Jiann-Der Lee; Tsung-I Peng; Tsong-Hai Lee
Journal:  Int J Environ Res Public Health       Date:  2020-01-18       Impact factor: 3.390

10.  Association of triglyceride-glucose index with clinical outcomes in patients with acute ischemic stroke receiving intravenous thrombolysis.

Authors:  Emma M S Toh; Amanda Y L Lim; Chua Ming; Leonard L L Yeo; Ching-Hui Sia; Bryce W Q Tan; Aloysius S T Leow; Jamie S Y Ho; Bernard P L Chan; Vijay Kumar Sharma; Benjamin Y Q Tan
Journal:  Sci Rep       Date:  2022-01-31       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.